| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14740338.2016.1145654 |
| P698 | PubMed publication ID | 26799331 |
| P50 | author | Giuliana Alimena | Q66370852 |
| Massimo Breccia | Q66370920 | ||
| P2093 | author name string | Gioia Colafigli | |
| Matteo Molica | |||
| P2860 | cites work | Systematic review of dasatinib in chronic myeloid leukemia | Q24596026 |
| Ponatinib in refractory Philadelphia chromosome-positive leukemias | Q27851967 | ||
| Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib | Q29999611 | ||
| Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. | Q30891587 | ||
| 15-deoxy-delta12,14-PGJ2 enhances platelet production from megakaryocytes | Q33380951 | ||
| Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). | Q33398716 | ||
| A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias | Q33411250 | ||
| Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up | Q33414487 | ||
| Severe thrombocytopenia after dasatinib treatment in a patient with Philadelphia chromosome-positive chronic myeloid leukemia. | Q33422727 | ||
| Chronic myelogenous leukemia: biology and therapy | Q33700942 | ||
| Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia | Q33828570 | ||
| Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. | Q33997854 | ||
| Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment | Q34268535 | ||
| Congestive heart failure is a rare event in patients receiving imatinib therapy | Q34621382 | ||
| Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. | Q34639998 | ||
| Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia | Q35008618 | ||
| Molecular mechanisms of transformation by the BCR-ABL oncogene | Q35143823 | ||
| Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib | Q35265868 | ||
| Regulation of the c-Abl and Bcr-Abl tyrosine kinases | Q35621355 | ||
| Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) | Q35694453 | ||
| Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation | Q35844144 | ||
| The development of imatinib as a therapeutic agent for chronic myeloid leukemia | Q35993288 | ||
| Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia | Q36708942 | ||
| Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors | Q37461942 | ||
| Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia | Q37498272 | ||
| Cardiotoxicity induced by tyrosine kinase inhibitors | Q37593059 | ||
| Current therapeutics and practical management strategies for pulmonary arterial hypertension | Q37915711 | ||
| Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia | Q37999439 | ||
| Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors | Q38087737 | ||
| Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs | Q38181111 | ||
| Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review. | Q38527941 | ||
| Clinical features of pulmonary arterial hypertension in patients receiving dasatinib | Q38568955 | ||
| Bosutinib for Chronic Myeloid Leukemia | Q38835127 | ||
| Dasatinib inhibits proinflammatory functions of mature human neutrophils | Q41885572 | ||
| The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply). | Q42708667 | ||
| Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia | Q42958726 | ||
| Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies | Q43178207 | ||
| Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia | Q43262982 | ||
| Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population | Q44306071 | ||
| Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study | Q44459252 | ||
| Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st | Q45024357 | ||
| Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy | Q46084072 | ||
| Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia | Q46090252 | ||
| Pulmonary arterial hypertension in patients treated by dasatinib | Q46176185 | ||
| Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient | Q46185511 | ||
| Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia | Q46262660 | ||
| An evaluation of the cardiotoxicity of imatinib mesylate | Q46583056 | ||
| Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience | Q46974546 | ||
| Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase | Q48070812 | ||
| Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia. | Q50998286 | ||
| Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment. | Q51107664 | ||
| Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. | Q51373837 | ||
| Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. | Q52884682 | ||
| Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. | Q53098953 | ||
| Severe peripheral arterial disease during nilotinib therapy. | Q54419090 | ||
| Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. | Q54446241 | ||
| Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. | Q54536381 | ||
| Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences. | Q54567948 | ||
| Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure | Q57731587 | ||
| Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o | Q58023854 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic myeloid leukemia | Q729735 |
| leukemia | Q29496 | ||
| P304 | page(s) | 525-533 | |
| P577 | publication date | 2016-01-22 | |
| P1433 | published in | Expert Opinion on Drug Safety | Q5421206 |
| P1476 | title | Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia | |
| P478 | volume | 15 |
| Q47139100 | Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells |
| Q42367946 | Development of a protease-resistant reporter to quantify BCR-ABL activity in intact cells |
| Q42011392 | Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. |
| Q38789049 | Second line small molecule therapy options for treating chronic myeloid leukemia |
Search more.